Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that testosterone may promote glioblastoma progression by being converted into dihydrotestosterone, which enhances cell proliferation, migration, and invasion in GBM cell lines.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This review discusses the evaluation and management of male baldness and related conditions, but reports no new clinical results.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

This article examines 5 alpha-reductase inhibitors and their link to persistent sexual dysfunction, but it reports no new clinical findings.

This study found that co-administering glucocorticoids with 5α-reductase inhibitors exacerbated the adverse metabolic effects of glucocorticoids in healthy men.

This article reviews factors influencing hair growth and treatment options for androgenetic alopecia, but it reports no new clinical results on their effectiveness.

This paper provides an overview of modern hair transplantation techniques and discusses the importance of patient selection and medication use for male pattern hair loss, but it reports no new results.

This review summarizes recent therapeutic advancements in treating various forms of alopecia, including new applications of oral minoxidil, dutasteride, finasteride, Janus kinase inhibitors, and novel hair transplant techniques, without presenting original research results.

This article reviews the challenges of treating frontal fibrosing alopecia and the potential role of hair transplantation, noting the lack of effective medical treatments and uncertainty surrounding transplant outcomes.

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

This study suggests that certain Dibenzo derivatives may be promising candidates for prostate cancer treatment due to their potential interactions with the androgen receptor and 5α-reductase enzyme.

This letter reports no new findings and discusses potential concerns regarding 5-alpha reductase inhibitors on lung function, suggesting a reason for discontinuation during the COVID-19 pandemic.

In this review and meta-analysis, the authors concluded that 5α-reductase inhibitor therapy is not consistently associated with significant increases in serum testosterone levels in men.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This review examines changes in hair physiology and treatment options for transgender patients on hormonal therapy but reports no new clinical findings, offering treatment recommendations based on the authors' experiences.

This study identified the expression of 5αR1 and 5αR3 enzymes in canine skin, which may advance understanding and treatment of alopecia X.

This review summarizes the current treatment modalities for frontal fibrosing alopecia and provides a practical guide for clinicians, but reports no new clinical results.

This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.

In this study, 5α-reductase inhibitors were found to have no significant impact on preventing tumorigenesis or progression in in vitro models of urothelial cancer.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

This study found that 5α-reductase inhibitors significantly reduced low-grade prostate cancer incidence in men but nearly doubled the incidence of high-grade prostate cancers.

This review discusses the role of androgens in male sexual differentiation and characteristics and reports no new clinical results; it emphasizes the androgen dependence of male pattern scalp hair loss.

In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.

This study on rats found that finasteride and dutasteride increased collagen density in penile tissues and caused changes in prostate cells, but did not significantly alter erectile pressures compared to controls.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

This study found that both finasteride and dutasteride led to morphological and functional kidney damage in rats, with more severe effects observed in the dutasteride group.